Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy Thumbnail Image Read more about Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 EHA Annual Meeting Thumbnail Image Read more about MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 EHA Annual Meeting
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress Thumbnail Image Read more about Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association Thumbnail Image Read more about Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
MorphoSys Highlights Potential of Its Oncology Pipeline at 2023 ASCO Annual Meeting Thumbnail Image Read more about MorphoSys Highlights Potential of Its Oncology Pipeline at 2023 ASCO Annual Meeting
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023 Thumbnail Image Read more about Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting Thumbnail Image Read more about NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting
Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting Thumbnail Image Read more about Biotheryx Presents Preclinical CDK4/6 and SOS1 Protein Degrader Data at AACR 2023 Annual Meeting
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets Thumbnail Image Read more about Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets
